Astrana Health (ASTH) vs Insperity (NSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Insperity (NSP) has outperformed Astrana Health (ASTH) over the past year, gaining 40.4% versus a gain of 28.4%. Over five years, NSP leads with a -58.2% price change compared with -69.4% for ASTH. Insperity is the larger company by market cap ($1.84 billion vs $1.44 billion), about 1.3 times the size, while Astrana Health is growing revenue faster (+56.4% vs +3.5%).
On valuation, Astrana Health trades at a lower forward P/E (8.3x vs 18.6x for Insperity). Insperity pays a dividend yielding 4.96%, while Astrana Health does not currently pay one. Astrana Health converts more of its revenue into profit, with a net margin of 0.7% versus -0.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASTH | NSP |
|---|---|---|
| Share price | $28.90 | $48.38 |
| Market cap | $1.44B | $1.84B |
| 1-day change | +0.77% | +2.33% |
| YTD return | +16.49% | +24.95% |
| 1-year return | +28.44% | +40.39% |
| 5-year return | -69.44% | -58.20% |
| P/E ratio (TTM) | 26.76 | 691.14 |
| Forward P/E | 8.30 | 18.61 |
| EPS (TTM) | $1.08 | $0.07 |
| Dividend yield | 0.00% | 4.96% |
| Annual dividend | $0.00 | $2.40 |
| Revenue (latest FY) | $3.18B | $6.81B |
| Revenue growth (YoY) | +56.39% | +3.51% |
| Net income (latest FY) | $22.49M | $-7.00M |
| Gross margin | 10.73% | 13.21% |
| Operating margin | 2.47% | -0.15% |
| Net margin | 0.71% | -0.10% |
| 52-week high | $51.60 | $55.90 |
| 52-week low | $18.08 | $18.57 |
| Distance from 52-week high | -43.99% | -13.45% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +79.55% | +10.07% |
| Average volume | 377.18K | 410.34K |
| Shares outstanding | 49.67M | 38.10M |
| Employees | 3,000 | 305,359 |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Industry | Professional Services | Professional Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NSP has outperformed ASTH by 12.0 percentage points over the past year.
- Insperity trades at a higher earnings multiple (691.1x vs 26.8x trailing P/E).
- Insperity offers a meaningfully higher dividend yield (4.96% vs 0.00%).
- Astrana Health grew revenue faster in its latest fiscal year (+56.39% vs +3.51%).
About Astrana Health
ASTH stock →Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement.
Consumer Discretionary · Professional Services · 3,000 employees
About Insperity
NSP stock →Insperity, Inc. engages in the provision of human resources (HR) and business solutions to improve business performance for small and medium-sized businesses primarily in the United States.
Consumer Discretionary · Professional Services · 305,359 employees
ASTH vs NSP FAQ
Which is bigger, Astrana Health or Insperity?
Insperity (NSP) is larger, with a market capitalization of $1.84B compared with $1.44B for Astrana Health (ASTH).
Which stock has performed better over the past year, ASTH or NSP?
NSP returned +40.39% over the past 12 months, compared with +28.44% for ASTH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ASTH or NSP?
ASTH has the lower trailing P/E at 26.8, versus 691.1 for NSP. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Astrana Health or Insperity?
Insperity pays a dividend yielding 4.96%, while Astrana Health does not currently pay a regular dividend.
Are Astrana Health and Insperity in the same industry?
Yes. Both are classified in the Professional Services industry within the Consumer Discretionary sector.